Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1153549 | 0.83 | HTT (0.38) | HTTCYP2C19CYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL13027401 | 0.81 | HTT (0.45) | HTTCYP2C19CYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL218138 | 0.81 | HTT (0.45) | HTTCYP2C19CYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL4075794 | 0.80 | CASP1 (0.41) | ALDH1A1CYP3A4IDO1TDO2TSHR | |
| SCHEMBL5351521 | 0.77 | ALDH1A1 (0.36) | HTTALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL1153651 | 0.77 | CYP2C19 (0.37) | HTTCYP2C19CYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL777870 | 0.75 | ALDH1A1 (0.55) | ALDH1A1CYP3A4KMT2ACYP19A1TSHR | |
| SCHEMBL28545488 | 0.74 | ALDH1A1 (0.43) | HTTCYP2C19CYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL18663548 | 0.73 | IDO1 (0.48) | HTTCYP2C19CYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL11358290 | 0.73 | EIF2AK2 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-8604023-B2 | 1,4-benzodiazepinone compounds and their use in treating cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-8461153-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2470020-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | The Regents of the University of Michigan (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8188072-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011035124-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2010121164-A2 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-2217576-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | The Regents of the University of Michigan (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061916-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | HTT 4639/4885CYP2C19 296/4885CYP2C9 827/4885 |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | HTR4, HTR1A, HTR3B | HTT 2586/4885CYP2C19 102/4885CYP2C9 272/4885 |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | HTT 4639/4885CYP2C19 296/4885CYP2C9 827/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | HTT 4639/4885CYP2C19 296/4885CYP2C9 827/4885 |
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | TPH1, GABBR1, RORC | HTT 2433/4885CYP2C19 171/4885CYP2C9 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.